{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034667","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.132790+00:00","generated_at":"2026-06-04T09:58:27.627109+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Dianthus reports FY2023 net loss $43.6M, cash $389M; Phase 2 gMG trial initiated","bullets":["FY2023 net loss $43.6M ($8.45/share), R&D $32.8M, G&A $18.2M.","Pro forma cash $389M (including $216M net from Jan 2024 PIPE); runway to 2H 2027.","Phase 2 MaGic gMG trial initiated Feb 2024; top-line data expected 2H 2025.","Phase 2 trials planned: MMN (Q2 2024) and CIDP (2H 2024).","Jeffrey Stavenhagen appointed CSO in Nov 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034667","json":"https://secwatch.observer/filing/0000950170-24-034667.json","markdown":"https://secwatch.observer/filing/0000950170-24-034667.md","text":"https://secwatch.observer/filing/0000950170-24-034667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024034667/0000950170-24-034667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024034667/dnth-20240321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:58:27.627109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"852fe4f74be851309f5a36e339dc41c7df9fa9fb","claim":"Dianthus Therapeutics, Inc. /DE/ reported the year ended December 31, 2023 results: net income $43.6 million, EPS $8.45 net loss per share (basic and diluted).","evidence_excerpt":"Net loss for the year ended December 31, 2023 was $43.6 million or $8.45 net loss per share (basic and diluted)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000095017024034667/0000950170-24-034667-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"$43.6 million"},{"label":"EPS","value":"$8.45 net loss per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}